0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

QUININE DERIVATIVES AND SPECIFIC IMMUNE SERUM IN THE TREATMENT OF PNEUMOCOCCUS INFECTION

HOBART A. REIMANN, M.D.; JOHANNES K. MOEN, M.D.
Arch Intern Med (Chic). 1932;50(2):276-282. doi:10.1001/archinte.1932.00150150108011.
Text Size: A A A
Published online

From the replies returned by twenty-five prominent German clinicians in response to questionnaires,1 it is evident that specific treatment of lobar pneumonia with immune serum has not as yet been generally accepted. Even in this country, an inquiry revealed that many physicians still rely on quinine derivatives and do not employ specific immune serum in treating lobar pneumonia. In view of the reports of Cole,2 Cecil and Sutliff,3 Park, Bullowa and Rosenbluth4 and others, showing the beneficial effects of type I serum in treating type I infections in a large number of patients, it seems unfortunate that quinine is still being used to the exclusion of specific serotherapy.

Quinine was introduced in the treatment of pneumonia about fifty years ago, chiefly by Jürgenson and Aufrecht. A new compound, ethylhydrocupreine, was popularized by Morgenroth and his associates in 1911. Ethylhydrocupreine is more pneumococcicidal than quinine in vitro

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();